Fig. 4From: Retrospective analysis of safety and efficacy of enhanced recovery pathways in stage II–III colorectal cancer patients submitted to surgery and adjuvant therapySurgical cost of patients. *Fewer ¥/patient than those of FTLCO, CSLFO, and OSLFO cohortsBack to article page